As the antibody drug conjugate (ADC) market continues to grow rapidly, the need for specialized manufacturing expertise has never been greater. Lonza, a leading CDMO partner, provides an end‑to‑end offering that simplifies the value chain and accelerates progress from early development to clinical and commercial manufacturing. With deep ADC expertise and extensive experience, we deliver high‑quality, commercially viable processes from pre‑clinical stages through to large‑scale production.
Access our whitepaper to discover how Lonza’s integrated solutions can streamline complex workflows, reduce risk, and accelerate your path to market.
